
Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
“I am concerned about decreased federal support impacting urologic clinical practices and research progress,” Arthur L. Burnett, II, MD, MBA, told Urology Times.
To get weekly news from the leading news source for urologists,





